|
Press Release |
07 June 2010 |
LiDCO Group Plc
("LiDCO" or the "Company")
2010 Annual Report and Accounts and Notice of AGM
In accordance with Rule 20 of the AIM Rules, LiDCO (AIM:LID), the cardiovascular monitoring company, confirms that the Annual Report and Accounts for the year ended 31 January 2010, the Notice of the Annual General Meeting and the Form of Proxy were posted to shareholders on 2 June 2010 and details are available to review on the Company's website at www.lidco.com.
The Company's Annual General Meeting is to be held on Tuesday 29 June 2010 at the offices of Abchurch Communications, 125 Old Broad Street, London EC2N 1AR.
- ENDS -
For more information please contact:
|
LiDCO Group Plc |
|
|
Terry O'Brien - Chief Executive John Rowland - Company Secretary |
Tel: +44 (0)20 7749 1500 |
|
FinnCap |
|
|
Geoff Nash / Stephen Norcross / Henrik Persson |
+44 (0)20 7600 1658 |
Media enquiries
|
Abchurch Communications |
|
|
Heather Salmond / Joanne Shears / Simone Elviss |
+44 (0)20 7398 7728 |
|
|
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:
* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)
* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery. The benefits are:
|
· |
Early and rapid warning of hemodynamic change |
|
· |
Aids choice of therapeutic route: fluid or drug |
|
· |
Quantification of hemodynamic response, particularly stroke volume |
|
· |
Guides more effective delivery of fluids - the right amount at the right time |
|
· |
Advanced hemodynamic care has been shown to contribute to: - Reduced morbidity and complications, length of stay & overall cost of care |
* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.
* LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.
LiDCO's Distribution Network:
The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.